10 Best Diabetes Stocks To Buy Under $10

4. Fractyl Health, Inc. (NASDAQ:GUTS)

Share Price as of the Close of December 26: $2.06

Fractyl Health, Inc. (NASDAQ:GUTS) is a company dedicated to transforming the treatment of type 2 diabetes (T2D) and obesity by developing therapies that address the root causes of these metabolic diseases rather than just managing symptoms. Its key products include the Revita DMR System which is a minimally invasive therapy that uses a balloon catheter to regenerate the duodenum and combat dysfunction linked to high-fat, high-sugar diets, and Rejuva, a gene therapy platform designed to modify pancreatic islet cells and enable long-term remission of T2D and obesity by improving metabolic hormone function.

Fractyl Health, Inc. (NASDAQ:GUTS)’s Q3 2024 financial report highlights stable revenue from its pilot commercial launch in Germany, with increased expenses reflecting progress in clinical and development programs. R&D costs rose to $19.0 million which was driven by advancements in the REMAIN-1 and REVITALIZE-1 trials and the Rejuva program. SG&A expenses increased to $4.8 million due to personnel costs and professional services. The company reported a net loss of $23.2 million, up from $15.7 million in Q3 2023, mainly due to higher operating expenses and non-cash losses from notes payable valuation changes.

The corporation maintains a strong cash position of $84.7 million as of September 30, 2024, expected to sustain operations into Q4 2025. Key milestones include mid-point data from REMAIN-1 in Q2 2025 and topline results from REVITALIZE-1 in mid-2025. Regulatory achievements, such as the CE mark in Germany and FDA Breakthrough Device Designation, bolster its market potential. Investors remain optimistic about its innovative therapies and forthcoming clinical data.

Fractyl Health, Inc. (NASDAQ:GUTS) presented promising weight maintenance and metabolic benefit data for Revita and Rejuva at ObesityWeek 2024. Additionally, the company is enrolling patients in its German Real-World Registry Study, with new data expected in Q1 2025 to further validate Revita’s clinical potential.